百济神州在2025年欧洲血液学协会年会上展示CLL和MCL治疗领域的突破性临床试验数据

百济神州
Jun 12

新一代试验性疗法临床结果显示出深度且持久的缓解潜力,支持推进其关键性研究及未来药政注册BCL2抑制剂索托克拉联合百悦泽®1期研究结果取得了深度缓解的临床结果——R/R CLL患者和R/R MCL患者ORR分别达到96%和79%——与此同时未发现新的安全性信号BTK降解剂BGB-16673的研究结果显示该药物用于难以治疗人群取得强劲早期有效性美国加州圣卡洛斯——百济神州有限公司(纳斯达克代码:ONC...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10